Jazz Pharmaceuticals PLC

• Country

  Ireland; Republic of

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Pharmaceuticals

• Sub-sector

  Health Care

• Capitalization (millions of $)

  6894.1

• Ticker

  JAZZ.O

• ISIN

  IE00B4Q5ZN47

• IPO date

  2012-01-18

• Availability on Russian exchanges

  No

• Reporting for

  2024-02-28

• Date fact. publication of reports

  2023-12-31

Jazz Pharmaceuticals Public Limited Company is a biopharmaceutical company. The Company is focused on developing and commercializing products that address unmet medical needs. The Company has a diverse portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. The Company's lead marketed products include Xyrem (sodium oxybate oral solution) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze for the treatment of acute lymphoblastic leukemia (ALL), and Defitelio (defibrotide) for the treatment of severe hepatic veno-occlusive disease (VOD). The Company also commercializes Prialt, an intrathecally administered infusion of ziconotide, approved by the FDA for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or intrathecal morphine.